bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Authors: Lee Hansol , Ferguson Angela L. , Quek Camelia , Vergara Ismael A. , Pires daSilva Ines , Allen Ruth , Gide Tuba Nur , Conway Jordan W. , Koufariotis Lambros T. , Hayward Nicholas K. , Waddell Nicola , Carlino Matteo S. , Menzies Alexander M. , Saw Robyn P.M. , Shklovskaya Elena , Rizos Helen , Lo Serigne , Scolyer Richard A. , Long Georgina V. , Palendira Umaimainthan , Wilmott James S.
Published: April 2023

AbstractPurpose:
This study characterizes intratumoral macrophage populations within baseline melanoma biopsies from patients with advanced melanoma who received either anti-PD-1 monotherapy or a combination with anti-CTLA-4. Particularly, FcγRIIIa (CD16)-expressing macrophage densities were investigated for associations with response and progression-free survival.
Experimental Design:
Patients with advanced melanoma who received either anti-PD-1 monotherapy or combination anti-PD-1 and anti-CTLA-4 were retrospectively identified. Macrophage populations were analyzed within baseline melanoma biopsies via multiplex IHC in relation to treatment outcomes.
Results:
Patients who responded to combination immune checkpoint inhibitor contained higher CD16+ macrophage densities than those who did not respond (196 vs. 7 cells/mm2; P = 0.0041). There was no diffidence in CD16+ macrophage densities in the PD-1 monotherapy-treated patients based on response (118 vs. 89 cells/mm2; P = 0.29). A significantly longer 3-year progression-free survival was observed in combination-treated patients with high intratumoral densities of CD16+ macrophages compared with those with low densities (87% vs. 42%, P = 0.0056, n = 40). No association was observed in anti-PD-1 monotherapy-treated patients (50% vs. 47%, P = 0.4636, n = 50). Melanoma biopsies with high densities of CD16+ macrophages contained upregulated gene expression of critical T-cell recruiting chemokines (CXCL9, CXCL10, and CXCL11).
Conclusions:
Our data demonstrate that tumor microenvironments enriched with CD16+ macrophages are favorable for response to combination anti-PD-1 and anti-CTLA-4 therapy but not anti-PD-1 monotherapy. These data provides a potential biomarker of response for combination immunotherapies in patients with metastatic melanoma.
Data from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer
Authors: Chen Huang , Zhou Wenbo , Bian Aiwu , Zhang Qiansen , Miao Ying , Yin Xuan , Ye Jiangnan , Xu Shifen , Ti Chaowen , Sun Zhenliang , Zheng Jianghua , Chen Yihua , Liu Mingyao , Yi Zhengfang
Published: April 2023

AbstractPurpose:
Pancreatic cancer is the worst prognosis among all human cancers, and novel effective treatments are urgently needed. Signal transducer and activator of transcription 3 (STAT3) has been demonstrated as a promising target for pancreatic cancer. Meanwhile, selectively targeted STAT3 with small molecule remains been challenging.
Experimental Design:
To specifically identify STAT3 inhibitors, more than 1.3 million compounds were screened by structure-based virtual screening and confirmed with the direct binding assay. The amino acid residues that WB436B bound to were verified by induced-fit molecular docking simulation, RosettaLigand computations, and site-directed mutagenesis. On-target effects of WB436B were examined by microscale thermophoresis, surface plasmon resonance, in vitro kinase assay, RNA sequencing, and selective cell growth inhibition assessment. In vivo studies were performed in four animal models to evaluate effects of WB436B on tumor growth and metastasis. Kaplan–Meier analyses were used to assess survival.
Results:
WB436B selectively bound to STAT3 over other STAT families protein, and in vitro antitumor activities were improved by 10 to 1,000 fold than the representative STAT3 inhibitors. WB436B selectively inhibits STAT3-Tyr705 phosphorylation, STAT3 target gene expression, and the viability of STAT3-dependent pancreatic cancer cells. WB436B significantly suppresses tumor growth and metastasis in vivo and prolongs survival of tumor-bearing mice. Mechanistic studies showed that WB436B have unique binding sites located in STAT3 Src homology 2 domain.
Conclusions:
Our work presents the first-in-class selective STAT3 inhibitor WB436B as a potential therapeutic candidate for the treatment of pancreatic cancer.
Data from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial
Authors: Xu Jie , Xie Lu , Sun Xin , Liu Kuisheng , Liang Xin , Cai Zhenyu , Tang Xiaodong , Guo Wei
Published: April 2023

AbstractPurpose:
The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing sarcoma requires clarification.
Patients and Methods:
Patients with relapsed or refractory Ewing sarcoma were randomly assigned (1:1) to either a shorter d × 5 schedule (irinotecan 50 mg/m2/d D1–5, vincristine 1.4 mg/m2 D1) or protracted d × 5×2 schedule (irinotecan 20 mg/m2/d D1–5,8–12, vincristine 1.4 mg/m2 D1,8) together with temozolomide (100 mg/m2/d D1–5). Patients were treated every 3 weeks for up to eight cycles until progression or unacceptable toxic effects occurred. The primary endpoint was objective response rate at 12 weeks (ORR12w). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety.
Result:
A total of 46 patients presenting with relapsed or refractory Ewing sarcoma were randomly assigned to the d × 5 (n = 24) or d × 5×2 (n = 22) schedules. Median follow-up was 10.7 months in the d × 5 group and 8.3 months in the d × 5×2 group. ORR12w was lower for d × 5 (5/24; 20.8%) patients than for d × 5×2 (12/22; 54.5%; P = 0.019), but no significant difference was found in PFS (median PFS, 2.3 months for d × 5 vs. 4.3 months for d × 5×2) or OS (median OS, 14.8 months for d × 5 and 12.8 months for d × 5×2). Patients receiving the d × 5 schedule reported more grade 3 and 4 adverse events (AE) than those receiving d × 5×2, including diarrhea/abdominal pain and vomiting/nausea.
Conclusions:
The protracted d × 5×2 VIT schedule showed superior efficacy and favorable tolerability compared with the shorter d × 5 VIT schedule in patients with relapsed or refractory Ewing sarcoma.
Data from Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice
Authors: Kitzberger Carolin , Spellerberg Rebekka , Han Yang , Schmohl Kathrin A. , Stauss Christina , Zach Christian , Kälin Roland E. , Multhoff Gabriele , Eiber Matthias , Schilling Franz , Glass Rainer , Weber Wolfgang A. , Wagner Ernst , Nelson Peter J. , Spitzweg Christine
Published: April 2023

AbstractPurpose:
Mesenchymal stem cells (MSC) have emerged as cellular-based vehicles for the delivery of therapeutic genes in cancer therapy based on their inherent tumor-homing capability. As theranostic gene, the sodium iodide symporter (NIS) represents a successful target for noninvasive radionuclide-based imaging and therapy. In this study, we applied genetically engineered MSCs for tumor-targeted NIS gene transfer in experimental glioblastoma (GBM)—a tumor with an extremely poor prognosis.
Experimental Design:
A syngeneic, immunocompetent GL261 GBM mouse model was established by subcutaneous and orthotopic implantation. Furthermore, a subcutaneous xenograft U87 model was used. Bone marrow–derived MSCs were stably transfected with a NIS-expressing plasmid driven by the constitutively active cytomegalovirus promoter (NIS-MSC). After multiple or single intravenous injection of NIS-MSCs, tumoral iodide uptake was monitored in vivo using 123I-scintigraphy or 124I-PET. Following validation of functional NIS expression, a therapy trial with 131I was performed on the basis of the most optimal application regime as seen by 124I-PET imaging in the orthotopic approach.
Results:
A robust tumoral NIS-specific radionuclide accumulation was observed after NIS-MSC and radioiodide application by NIS-mediated in vivo imaging. NIS immunofluorescence staining of GBM and non-target tissues showed tumor-selective MSC homing along with NIS expression. Application of therapeutically effective 131I led to significantly delayed tumor growth and prolonged median survival after NIS-MSC treatment as compared with controls.
Conclusions:
A strong tumor-selective recruitment of systemically applied MSCs into GBM was found using NIS as reporter gene followed by successful therapeutic application of radioiodide demonstrating the potential use of NIS-based MSCs as therapy vehicles as a new GBM therapy approach.
Supplementary Fig. S1 from Autophagy inhibition enhances anthocyanin-induced apoptosis in hepatocellular carcinoma
Authors: Longo Luigia , Platini Francesca , Scardino Anna , Alabiso Oscar , Vasapollo Giuseppe , Tessitore Luciana
Published: April 2023

Supplementary Fig. S1 from Autophagy inhibition enhances anthocyanin-induced apoptosis in hepatocellular carcinoma
Supplementary Fig. S4 from Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Authors: Yagi Hiroshi , Yotsumoto Fusanori , Miyamoto Shingo
Published: April 2023

Supplementary Fig. S4 from Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Supplementary Fig. S1 from Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Authors: Yagi Hiroshi , Yotsumoto Fusanori , Miyamoto Shingo
Published: April 2023

Supplementary Fig. S1 from Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Supplementary Fig. S3 from Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Authors: Hussain Azhar R. , Ahmed Maqbool , Al-Jomah Naif A. , Khan Asma S. , Manogaran Pulicat , Sultana Mehar , Abubaker Jehad , Platanias Leonidas C. , Al-Kuraya Khawla S. , Uddin Shahab
Published: April 2023

Supplementary Fig. S3 from Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Supplementary Fig. S2 from Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Authors: Hussain Azhar R. , Ahmed Maqbool , Al-Jomah Naif A. , Khan Asma S. , Manogaran Pulicat , Sultana Mehar , Abubaker Jehad , Platanias Leonidas C. , Al-Kuraya Khawla S. , Uddin Shahab
Published: April 2023

Supplementary Fig. S2 from Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Supplementary Fig. S2 from Anti-CD30 diabody-drug conjugates with potent antitumor activity
Authors: Kim Kristine M. , McDonagh Charlotte F. , Westendorf Lori , Brown Lindsay L. , Sussman Django , Feist Tiffany , Lyon Robert , Alley Stephen C. , Okeley Nicole M. , Zhang Xinqun , Thompson Melissa C. , Stone Ivan , Gerber Hans-Peter , Carter Paul J.
Published: April 2023

Supplementary Fig. S2 from Anti-CD30 diabody-drug conjugates with potent antitumor activity
Supplementary Fig. S1 from Anti-CD30 diabody-drug conjugates with potent antitumor activity
Authors: Kim Kristine M. , McDonagh Charlotte F. , Westendorf Lori , Brown Lindsay L. , Sussman Django , Feist Tiffany , Lyon Robert , Alley Stephen C. , Okeley Nicole M. , Zhang Xinqun , Thompson Melissa C. , Stone Ivan , Gerber Hans-Peter , Carter Paul J.
Published: April 2023

Supplementary Fig. S1 from Anti-CD30 diabody-drug conjugates with potent antitumor activity
Supplementary Fig. S1 from Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Authors: Richards John O. , Karki Sher , Lazar Greg A. , Chen Hsing , Dang Wei , Desjarlais John R.
Published: April 2023

Supplementary Fig. S1 from Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Supplementary Table S1 from Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Authors: Liaw Tracy Y.E. , Salam Noeris K. , McKay Matthew J. , Cunningham Anne M. , Hibbs David E. , Kavallaris Maria
Published: April 2023

Supplementary Table S1 from Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Supplementary Fig. S1 legend from Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Authors: Liaw Tracy Y.E. , Salam Noeris K. , McKay Matthew J. , Cunningham Anne M. , Hibbs David E. , Kavallaris Maria
Published: April 2023

Supplementary Fig. S1 legend from Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Supplementary Fig. S1 from αvβ3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers
Authors: Belleri Mirella , Ribatti Domenico , Savio Monica , Stivala Lucia Anna , Forti Luca , Tanghetti Elena , Alessi Patrizia , Coltrini Daniela , Bugatti Antonella , Mitola Stefania , Nicoli Stefania , Vannini Vanio , Presta Marco
Published: April 2023

Supplementary Fig. S1 from αvβ3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers
Supplementary Fig. S2 from Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
Authors: Parsels Leslie A. , Morgan Meredith A. , Tanska Daria M. , Parsels Joshua D. , Palmer Brian D. , Booth R. John , Denny William A. , Canman Christine E. , Kraker Alan J. , Lawrence Theodore S. , Maybaum Jonathan
Published: April 2023

Supplementary Fig. S2 from Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
Supplementary Methods from In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin
Authors: Peng Li , Liu Ruiwu , Andrei Mirela , Xiao Wenwu , Lam Kit S.
Published: April 2023

Supplementary Methods from In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin
Supplementary Data from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Authors: Afshar Sepideh , Asai Tsuneaki , Morrison Sherie L.
Published: April 2023

Supplementary Data from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Supplementary Fig. S5 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Authors: Henderson Meredith C. , Shaw Yeng-Jeng Y. , Wang Hong , Han Haiyong , Hurley Laurence H. , Flynn Gary , Dorr Robert T. , Von Hoff Daniel D.
Published: April 2023

Supplementary Fig. S5 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Supplementary Fig. S2 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Authors: Henderson Meredith C. , Shaw Yeng-Jeng Y. , Wang Hong , Han Haiyong , Hurley Laurence H. , Flynn Gary , Dorr Robert T. , Von Hoff Daniel D.
Published: April 2023

Supplementary Fig. S2 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Supplementary Fig. S1 from Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin
Authors: Peklak-Scott Christina , Smitherman Pamela K. , Townsend Alan J. , Morrow Charles S.
Published: April 2023

Supplementary Fig. S1 from Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin
Supplementary Fig. S1 from Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Authors: Pchejetski Dimitri , Doumerc Nicolas , Golzio Muriel , Naymark Maria , Teissié Justin , Kohama Takafumi , Waxman Jonathan , Malavaud Bernard , Cuvillier Olivier
Published: April 2023

Supplementary Fig. S1 from Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Supplementary Figure 3 from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Authors: Jantscheff Peter , Schlesinger Martin , Fritzsche Juliane , Taylor Lenka A. , Graeser Ralph , Kirfel Gregor , Fürst Dieter O. , Massing Ulrich , Bendas Gerd
Published: April 2023

Supplementary Figure 3 from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Supplementary Figure 1A from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Authors: Jantscheff Peter , Schlesinger Martin , Fritzsche Juliane , Taylor Lenka A. , Graeser Ralph , Kirfel Gregor , Fürst Dieter O. , Massing Ulrich , Bendas Gerd
Published: April 2023

Supplementary Figure 1A from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Supplementary Fig. S1 from 1,1-Bis(3′-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth
Authors: Inamoto Teruo , Papineni Sabitha , Chintharlapalli Sudhakar , Cho Sung-Dae , Safe Stephen , Kamat Ashish M.
Published: April 2023

Supplementary Fig. S1 from 1,1-Bis(3′-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth
Supplementary Fig. S2 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Authors: Bataller Marc , Méndez Carmen , Salas José A. , Portugal José
Published: April 2023

Supplementary Fig. S2 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Supplementary Fig. S1 from Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
Authors: Sedic Mirela , Poznic Miroslav , Gehrig Peter , Scott Mike , Schlapbach Ralph , Hranjec Marijana , Karminski-Zamola Grace , Pavelic Kresimir , Pavelic Sandra Kraljevic
Published: April 2023

Supplementary Fig. S1 from Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
Supplementary Fig. S2 from Identification and characterization of small-molecule inhibitors of hepsin
Authors: Chevillet John R. , Park Gemma J. , Bedalov Antonio , Simon Julian A. , Vasioukhin Valeri I.
Published: April 2023

Supplementary Fig. S2 from Identification and characterization of small-molecule inhibitors of hepsin
Supplementary Fig. from Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-κB pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis
Authors: Kunnumakkara Ajaikumar B. , Ichikawa Haruyo , Anand Preetha , Mohankumar Chiramel J. , Hema Padmanabhan S. , Nair Mangalam S. , Aggarwal Bharat B.
Published: April 2023

Supplementary Fig. from Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-κB pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis
Supplementary Data from Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines
Authors: Greshock Joel , Cheng Jie , Rusnak David , Martin Anne Marie , Wooster Richard , Gilmer Tona , Lee Kwan , Weber Barbara L. , Zaks Tal
Published: April 2023

Supplementary Data from Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines
Supplementary Fig. S1 from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis
Authors: Raja Shruti M. , Chen Shuzhen , Yue Ping , Acker Timothy M. , Lefkove Benjamin , Arbiser Jack L. , Khuri Fadlo R. , Sun Shi-Yong
Published: April 2023

Supplementary Fig. S1 from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis
Supplementary Fig. S1 from EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Authors: Zhang Yuexing , Linn Douglas , Liu Zhenqiu , Melamed Jonathan , Tavora Fabio , Young Charles Y. , Burger Angelika M. , Hamburger Anne W.
Published: April 2023

Supplementary Fig. S1 from EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Supplementary Table S2 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Authors: Fischer Hendrik , Taylor Ninon , Allerstorfer Sigrid , Grusch Michael , Sonvilla Gudrun , Holzmann Klaus , Setinek Ulrike , Elbling Leonilla , Cantonati Heidelinde , Grasl-Kraupp Bettina , Gauglhofer Christine , Marian Brigitte , Micksche Michael , Berger Walter
Published: April 2023

Supplementary Table S2 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Supplementary Table S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Authors: Fischer Hendrik , Taylor Ninon , Allerstorfer Sigrid , Grusch Michael , Sonvilla Gudrun , Holzmann Klaus , Setinek Ulrike , Elbling Leonilla , Cantonati Heidelinde , Grasl-Kraupp Bettina , Gauglhofer Christine , Marian Brigitte , Micksche Michael , Berger Walter
Published: April 2023

Supplementary Table S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Supplementary Fig. S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Authors: Fischer Hendrik , Taylor Ninon , Allerstorfer Sigrid , Grusch Michael , Sonvilla Gudrun , Holzmann Klaus , Setinek Ulrike , Elbling Leonilla , Cantonati Heidelinde , Grasl-Kraupp Bettina , Gauglhofer Christine , Marian Brigitte , Micksche Michael , Berger Walter
Published: April 2023

Supplementary Fig. S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Supplementary Fig. S2 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Authors: Miyanaga Akihiko , Gemma Akihiko , Noro Rintaro , Kataoka Kiyoko , Matsuda Kuniko , Nara Michiya , Okano Tetsuya , Seike Masahiro , Yoshimura Akinobu , Kawakami Akiko , Uesaka Haruka , Nakae Hiroki , Kudoh Shoji
Published: April 2023

Supplementary Fig. S2 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Supplementary Fig. S3 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Authors: Ackler Scott , Xiao Yu , Mitten Michael J. , Foster Kelly , Oleksijew Anatol , Refici Marion , Schlessinger Sally , Wang Baole , Chemburkar Sanjay R. , Bauch Joy , Tse Christin , Frost David J. , Fesik Stephen W. , Rosenberg Saul H. , Elmore Steven W. , Shoemaker Alex R.
Published: April 2023

Supplementary Fig. S3 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Supplementary Fig. S2 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Authors: Ackler Scott , Xiao Yu , Mitten Michael J. , Foster Kelly , Oleksijew Anatol , Refici Marion , Schlessinger Sally , Wang Baole , Chemburkar Sanjay R. , Bauch Joy , Tse Christin , Frost David J. , Fesik Stephen W. , Rosenberg Saul H. , Elmore Steven W. , Shoemaker Alex R.
Published: April 2023

Supplementary Fig. S2 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Supplementary Fig. S2 from Adenoviral endoplasmic reticulum–targeted mda-7/interleukin-24 vector enhances human cancer cell killing
Authors: Pataer Abujiang , Hu Wenxian , Xiaolin Lu , Chada Sunil , Roth Jack A. , Hunt Kelly K. , Swisher Stephen G.
Published: April 2023

Supplementary Fig. S2 from Adenoviral endoplasmic reticulum–targeted mda-7/interleukin-24 vector enhances human cancer cell killing
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Authors: Fournel Marielle , Bonfils Claire , Hou Yu , Yan Pu Theresa , Trachy-Bourget Marie-Claude , Kalita Ann , Liu Jianhong , Lu Ai-Hua , Zhou Nancy Z. , Robert Marie-France , Gillespie Jeffrey , Wang James J. , Ste-Croix Hélène , Rahil Jubrail , Lefebvre Sylvain , Moradei Oscar , Delorme Daniel , MacLeod A. Robert , Besterman Jeffrey M. , Li Zuomei
Published: April 2023

Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Supplementary Material from Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90
Authors: Hernández Agustín , López-Lluch Guillermo , Bernal Juan A. , Navas Plácido , Pintor-Toro José A.
Published: April 2023

Supplementary Material from Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90
Supplementary Table S4 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Authors: Song Dongweon , Chaerkady Raghothama , Tan Aik Choon , García-García Elena , Nalli Anuradha , Suárez-Gauthier Ana , López-Ríos Fernando , Zhang Xian Feng , Solomon Anna , Tong Jeffrey , Read Margaret , Fritz Christian , Jimeno Antonio , Pandey Akhilesh , Hidalgo Manuel
Published: April 2023

Supplementary Table S4 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Supplementary Table from Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity
Authors: Sullivan Richard , Paré Geneviève C. , Frederiksen Lisa J. , Semenza Gregg L. , Graham Charles H.
Published: April 2023

Supplementary Table from Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity
Supplementary Table S1 from Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma
Authors: Payne Cathy A. , Maleki Sanaz , Messina Marinella , O'Sullivan Maree G. , Stone Glenn , Hall Nathan R. , Parkinson Jonathon F. , Wheeler Helen R. , Cook Raymond J. , Biggs Michael T. , Little Nicholas S. , Teo Charles , Robinson Bruce G. , McDonald Kerrie L.
Published: April 2023

Supplementary Table S1 from Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma
Supplementary Table 1 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Authors: Søkilde Rolf , Kaczkowski Bogumil , Podolska Agnieszka , Cirera Susanna , Gorodkin Jan , Møller Søren , Litman Thomas
Published: April 2023

Supplementary Table 1 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Supplementary Methods, Figures 1-5, Table 5 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Authors: Søkilde Rolf , Kaczkowski Bogumil , Podolska Agnieszka , Cirera Susanna , Gorodkin Jan , Møller Søren , Litman Thomas
Published: April 2023

Supplementary Methods, Figures 1-5, Table 5 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Supplementary Table S3 from NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells
Authors: John-Aryankalayil Molykutty , Palayoor Sanjeewani T. , Cerna David , Falduto Michael T. , Magnuson Scott R. , Coleman C. Norman
Published: April 2023

Supplementary Table S3 from NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells
Supplementary Figure Legends from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Authors: Hou Xiaonan , Huang Fei , Carboni Joan M. , Flatten Karen , Asmann Yan W. , Ten Eyck Cynthia , Nakanishi Takeo , Tibodeau Jennifer D. , Ross Douglas D. , Gottardis Marco M. , Erlichman Charles , Kaufmann Scott H. , Haluska Paul
Published: April 2023

Supplementary Figure Legends from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Supplementary Figure 3 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Authors: Hou Xiaonan , Huang Fei , Carboni Joan M. , Flatten Karen , Asmann Yan W. , Ten Eyck Cynthia , Nakanishi Takeo , Tibodeau Jennifer D. , Ross Douglas D. , Gottardis Marco M. , Erlichman Charles , Kaufmann Scott H. , Haluska Paul
Published: April 2023

Supplementary Figure 3 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Supplementary Figure 2A from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Authors: Hou Xiaonan , Huang Fei , Carboni Joan M. , Flatten Karen , Asmann Yan W. , Ten Eyck Cynthia , Nakanishi Takeo , Tibodeau Jennifer D. , Ross Douglas D. , Gottardis Marco M. , Erlichman Charles , Kaufmann Scott H. , Haluska Paul
Published: April 2023

Supplementary Figure 2A from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Supplementary Table S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Authors: Ding Yan , Boguslawski Elissa A. , Berghuis Bree D. , Young John J. , Zhang Zhongfa , Hardy Kim , Furge Kyle , Kort Eric , Frankel Arthur E. , Hay Rick V. , Resau James H. , Duesbery Nicholas S.
Published: April 2023

Supplementary Table S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Supplementary Fig. S3 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Authors: Ding Yan , Boguslawski Elissa A. , Berghuis Bree D. , Young John J. , Zhang Zhongfa , Hardy Kim , Furge Kyle , Kort Eric , Frankel Arthur E. , Hay Rick V. , Resau James H. , Duesbery Nicholas S.
Published: April 2023

Supplementary Fig. S3 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Supplementary Fig. S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Authors: Ding Yan , Boguslawski Elissa A. , Berghuis Bree D. , Young John J. , Zhang Zhongfa , Hardy Kim , Furge Kyle , Kort Eric , Frankel Arthur E. , Hay Rick V. , Resau James H. , Duesbery Nicholas S.
Published: April 2023

Supplementary Fig. S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Supplementary Table S3 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Authors: Orth James D. , Tang Yangzhong , Shi Jade , Loy Clement T. , Amendt Christiane , Wilm Claudia , Zenke Frank T. , Mitchison Timothy J.
Published: April 2023

Supplementary Table S3 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Supplementary Fig. S8 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Authors: Orth James D. , Tang Yangzhong , Shi Jade , Loy Clement T. , Amendt Christiane , Wilm Claudia , Zenke Frank T. , Mitchison Timothy J.
Published: April 2023

Supplementary Fig. S8 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Supplementary Fig. S5 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Authors: Orth James D. , Tang Yangzhong , Shi Jade , Loy Clement T. , Amendt Christiane , Wilm Claudia , Zenke Frank T. , Mitchison Timothy J.
Published: April 2023

Supplementary Fig. S5 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Supplementary Fig. S1 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Authors: Orth James D. , Tang Yangzhong , Shi Jade , Loy Clement T. , Amendt Christiane , Wilm Claudia , Zenke Frank T. , Mitchison Timothy J.
Published: April 2023

Supplementary Fig. S1 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Supplementary Figure 1 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Authors: Tripathi Rakshamani , Samadder Tanmoy , Gupta Sarika , Surolia Avadhesha , Shaha Chandrima
Published: April 2023

Supplementary Figure 1 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Supplementary Table S2 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
Authors: An Feng , Drummond Daryl C. , Wilson Shannon , Kirpotin Dmitri B. , Nishimura Stephen L. , Broaddus V. Courtney , Liu Bin
Published: April 2023

Supplementary Table S2 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
Supplementary Fig. S1 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
Authors: An Feng , Drummond Daryl C. , Wilson Shannon , Kirpotin Dmitri B. , Nishimura Stephen L. , Broaddus V. Courtney , Liu Bin
Published: April 2023

Supplementary Fig. S1 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
Supplementary Table S3 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Table S3 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Table S2 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Table S2 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Table S1 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Table S1 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Fig. S7 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Fig. S7 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Fig. S4 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Fig. S4 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Fig. S2 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Fig. S2 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Fig from Antimigratory effect of TK1-2 is mediated in part by interfering with integrin α2β1
Authors: Kim Hyun-Kyung , Oh Dae-Shik , Lee Sang-Bae , Ha Jung-Min , Joe Young Ae
Published: April 2023

Supplementary Fig from Antimigratory effect of TK1-2 is mediated in part by interfering with integrin α2β1
Supplementary Methods from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Authors: Ross-Macdonald Petra , de Silva Heshani , Guo Qi , Xiao Hong , Hung Chen-Yi , Penhallow Becky , Markwalder Jay , He Liqi , Attar Ricardo M. , Lin Tai-an , Seitz Steven , Tilford Charles , Wardwell-Swanson Judith , Jackson Donald
Published: April 2023

Supplementary Methods from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Supplementary Figures 1-7 from A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Authors: Wang Hongbo , Ma Xujun , Ren Shumei , Buolamwini John K. , Yan Chunhong
Published: April 2023

Supplementary Figures 1-7 from A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Supplementary Table S1 from Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer
Authors: Balagurunathan Yoganand , Morse David L. , Hostetter Galen , Shanmugam Vijayalakshmi , Stafford Phillip , Shack Sonsoles , Pearson John , Trissal Maria , Demeure Michael J. , Von Hoff Daniel D. , Hruby Victor J. , Gillies Robert J. , Han Haiyong
Published: April 2023

Supplementary Table S1 from Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer
Supplementary Data from Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
Authors: Carnahan Josette , Beltran Pedro J. , Babij Carol , Le Quynh , Rose Mark J. , Vonderfecht Steven , Kim Joseph L. , Smith Adrian L. , Nagapudi Karthik , Broome Martin A. , Fernando Manory , Kha Hue , Belmontes Brian , Radinsky Robert , Kendall Richard , Burgess Teresa L.
Published: April 2023

Supplementary Data from Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
Supplementary Fig. S3 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Authors: Casado José A. , Río Paula , Marco Esther , García-Hernández Verónica , Domingo Alberto , Pérez Laura , Tercero Juan Carlos , Vaquero Juan José , Albella Beatriz , Gago Federico , Bueren Juan A.
Published: April 2023

Supplementary Fig. S3 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Supplementary Fig. S2 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Authors: Casado José A. , Río Paula , Marco Esther , García-Hernández Verónica , Domingo Alberto , Pérez Laura , Tercero Juan Carlos , Vaquero Juan José , Albella Beatriz , Gago Federico , Bueren Juan A.
Published: April 2023

Supplementary Fig. S2 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Supplementary Data from Quantification of endothelial cell–targeted anti–Bcl-2 therapy and its suppression of tumor growth and vascularization
Authors: Jain Harsh Vardhan , Nör Jacques Eduardo , Jackson Trachette Levon
Published: April 2023

Supplementary Data from Quantification of endothelial cell–targeted anti–Bcl-2 therapy and its suppression of tumor growth and vascularization
Supplementary Fig. S1 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Authors: Casado José A. , Río Paula , Marco Esther , García-Hernández Verónica , Domingo Alberto , Pérez Laura , Tercero Juan Carlos , Vaquero Juan José , Albella Beatriz , Gago Federico , Bueren Juan A.
Published: April 2023

Supplementary Fig. S1 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Supplementary Table from Aminopeptidase inhibition as a targeted treatment strategy in myeloma
Authors: Moore Hannah E. , Davenport Emma L. , Smith Emma M. , Muralikrishnan Srikanth , Dunlop Alan S. , Walker Brian A. , Krige David , Drummond Alan H. , Hooftman Leon , Morgan Gareth J. , Davies Faith E.
Published: April 2023

Supplementary Table from Aminopeptidase inhibition as a targeted treatment strategy in myeloma
Supplementary Data from Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
Authors: Squires Matthew S. , Feltell Ruth E. , Wallis Nicola G. , Lewis E. Jonathan , Smith Donna-Michelle , Cross David M. , Lyons John F. , Thompson Neil T.
Published: April 2023

Supplementary Data from Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
Supplementary Table 2 from Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Authors: O'Brien Neil A. , Browne Brigid C. , Chow Lucy , Wang Yuhua , Ginther Charles , Arboleda Jane , Duffy Michael J. , Crown John , O'Donovan Norma , Slamon Dennis J.
Published: April 2023

Supplementary Table 2 from Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Supplementary Figures 1-2 from Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models
Authors: Daouti Sherif , Higgins Brian , Kolinsky Kenneth , Packman Kathryn , Wang Huisheng , Rizzo Christine , Moliterni John , Huby Nicholas , Fotouhi Nader , Liu Mei , Goelzer Petra , Sandhu Harpreet K. , Li Jia Kui , Railkar Aruna , Heimbrook David , Niu Huifeng
Published: April 2023

Supplementary Figures 1-2 from Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models
Supplementary Fig from Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy
Authors: Jeon Yong Hyun , Choi Yun , Yoon Sun Och , Kim Chul Woo , Chung June-Key
Published: April 2023

Supplementary Fig from Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy
Supplementary Methods from A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Authors: Zhang Tao , Hamza Adel , Cao Xianhua , Wang Bing , Yu Shuwen , Zhan Chang-Guo , Sun Duxin
Published: April 2023

Supplementary Methods from A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Supplementary Fig. S7 from A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Authors: Zhang Tao , Hamza Adel , Cao Xianhua , Wang Bing , Yu Shuwen , Zhan Chang-Guo , Sun Duxin
Published: April 2023

Supplementary Fig. S7 from A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Supplementary Fig. S3 from A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells
Authors: Kim Byung Hak , Yin Chang-Hong , Guo Qianxu , Bach Erika A. , Lee Haeryun , Sandoval Claudio , Jayabose Somasundaram , Ulaczyk-Lesanko Agnieszka , Hall Dennis G. , Baeg Gyeong-Hun
Published: April 2023

Supplementary Fig. S3 from A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells
Supplementary Fig. S2 from A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells
Authors: Kim Byung Hak , Yin Chang-Hong , Guo Qianxu , Bach Erika A. , Lee Haeryun , Sandoval Claudio , Jayabose Somasundaram , Ulaczyk-Lesanko Agnieszka , Hall Dennis G. , Baeg Gyeong-Hun
Published: April 2023

Supplementary Fig. S2 from A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells
Supplementary Figure Legends from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Authors: Chetty Chandramu , Lakka Sajani S. , Bhoopathi Praveen , Gondi Christopher S. , Veeravalli Krishna Kumar , Fassett Daniel , Klopfenstein Jeffrey D. , Dinh Dzung H. , Gujrati Meena , Rao Jasti S.
Published: April 2023

Supplementary Figure Legends from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Supplementary Figure 3 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Authors: Chetty Chandramu , Lakka Sajani S. , Bhoopathi Praveen , Gondi Christopher S. , Veeravalli Krishna Kumar , Fassett Daniel , Klopfenstein Jeffrey D. , Dinh Dzung H. , Gujrati Meena , Rao Jasti S.
Published: April 2023

Supplementary Figure 3 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Supplementary Figure 2 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas
Authors: Hu Kaiji , Lee Cathy , Qiu Dexin , Fotovati Abbas , Davies Alastair , Abu-Ali Samah , Wai Daniel , Lawlor Elizabeth R. , Triche Timothy J. , Pallen Catherine J. , Dunn Sandra E.
Published: April 2023

Supplementary Figure 2 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas